These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 19910554)

  • 1. Long- or short-term hormones for locally advanced prostate cancer?
    Brower V
    J Natl Cancer Inst; 2009 Dec; 101(23):1606-8. PubMed ID: 19910554
    [No Abstract]   [Full Text] [Related]  

  • 2. [The question of intermittent hormonal treatment of cancer of the prostate].
    Boca P
    Acta Urol Belg; 1998 May; 66(2):17-20. PubMed ID: 9633121
    [No Abstract]   [Full Text] [Related]  

  • 3. The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer.
    Gleave M; Klotz L; Taneja SS
    Urol Oncol; 2009; 27(1):81-6. PubMed ID: 19111804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of intermittent androgen deprivation in prostate cancer.
    Boccon-Gibod L; Hammerer P; Madersbacher S; Mottet N; Prayer-Galetti T; Tunn U
    BJU Int; 2007 Oct; 100(4):738-43. PubMed ID: 17662079
    [No Abstract]   [Full Text] [Related]  

  • 5. [Intermittent hormonal treatment in prostatic cancer].
    Zerbib M; Conquy S
    Prog Urol; 1997 Dec; 7(6):1026-7. PubMed ID: 9490134
    [No Abstract]   [Full Text] [Related]  

  • 6. Intermittent androgen deprivation therapy: conventional wisdom versus evidence.
    Tombal B
    Eur Urol; 2009 Jun; 55(6):1278-80. PubMed ID: 19303201
    [No Abstract]   [Full Text] [Related]  

  • 7. A review of the use of histrelin acetate in the treatment of prostate cancer.
    Crawford ED
    BJU Int; 2009 Mar; 103 Suppl 2():14-22. PubMed ID: 19228148
    [No Abstract]   [Full Text] [Related]  

  • 8. Primary combined androgen blockade in localized disease and its mechanism.
    Namiki M; Kitagawa Y; Mizokami A; Koh E
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):303-15. PubMed ID: 18471788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Intermittent androgen blockade in prostatic carcinoma].
    Vachalovský V; Dvorácek J
    Cas Lek Cesk; 2002 Oct; 141(21):669-72. PubMed ID: 12564373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Watchful waiting beats androgen deprivation therapy in early prostate cancer.
    Brower V
    J Natl Cancer Inst; 2008 Nov; 100(21):1494-6. PubMed ID: 18957680
    [No Abstract]   [Full Text] [Related]  

  • 11. Intermittent androgen deprivation for locally advanced prostate cancer. Preliminary experience from an ongoing randomized controlled study of the South European urooncological group.
    Calais da Silva F; Bono A; Whelan P; Brausi M; Queimadelos M; Portillo J; Kirkali Z; Robertson C
    Oncology; 2003; 65 Suppl 1():24-8. PubMed ID: 12949430
    [No Abstract]   [Full Text] [Related]  

  • 12. Androgen deprivation therapy and prostate cancer duration.
    Williams SG; Pickles T; Buyyounouski MK
    J Clin Oncol; 2009 Dec; 27(34):e228; author reply e229. PubMed ID: 19884533
    [No Abstract]   [Full Text] [Related]  

  • 13. Androgen deprivation before prostate radiotherapy: how long is long enough?
    Parker C
    Lancet Oncol; 2011 May; 12(5):411-2. PubMed ID: 21440506
    [No Abstract]   [Full Text] [Related]  

  • 14. Prostate cancer--management of disseminated disease (intermittent androgen suppression).
    Lobel B; Richard F
    Acta Chir Iugosl; 2005; 52(4):11-2. PubMed ID: 16673586
    [No Abstract]   [Full Text] [Related]  

  • 15. [Early versus late hormonal treatment in advanced prostate cancer].
    Allepuz Losa C; Gil Martínez P; Gil Sanz MJ; Rioja Sanz LA
    Actas Urol Esp; 1999; 23(7):557-64. PubMed ID: 10488608
    [No Abstract]   [Full Text] [Related]  

  • 16. [Histological investigation of prostate cancer treated with hormonal agents].
    Azumi M; Saga Y; Hashimoto H; Kakizaki H
    Hinyokika Kiyo; 2006 Oct; 52(10):781-4. PubMed ID: 17131867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Quality of life of patients with locally-advanced prostate cancer as a criterium of therapeutic effectiveness].
    Kaprin AD; Kostin AA; Tsybul'skiĭ AD
    Vopr Onkol; 2009; 55(3):285-90. PubMed ID: 19670727
    [No Abstract]   [Full Text] [Related]  

  • 18. Leuprorelin, triptorelin: new indications. Locally advanced prostate cancer: minimally assessed me-toos.
    Prescrire Int; 2007 Dec; 16(92):243. PubMed ID: 18092407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re: Fritz H. Schröder, Karl-Heinz Kurth, Sophie D. Fossa, et al. Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a randomised controlled trial). Eur Urol 2009;55:14-22.
    Drewa T
    Eur Urol; 2009 May; 55(5):e82-3. PubMed ID: 18950934
    [No Abstract]   [Full Text] [Related]  

  • 20. Biased hormonal therapy duration analysis makes results uninterpretable.
    Tangen CM; Goldman BH; Swanson GP; Thompson IM
    J Clin Oncol; 2009 Nov; 27(33):e203; author reply e204. PubMed ID: 19786655
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.